good news! The latest Covid vaccine ‘Monovalent XBB.1.5’ is better than the old version. WHO recommends the vaccine to deal with the 2024 outbreak | The Bangkok Insight

Good news, the latest COVID vaccine “Monovalent

Medical Genome Center, Ramathibodi Hospital, posted on its Facebook page. Center for Medical Genomics stated that the World Health Organization (WHO) and the United States Food and Drug Administration (US FDA) are working together to recommend that COVID-19 vaccine manufacturers Change to using a single Omicron strain, XBB, as the inoculum or prototype for production.“Monovalent vaccine”

He also recommended that countries should prepare to switch to the XBB vaccine in order to prevent infection. and in time to prevent severe symptoms If infected with the mutant next year (2024), instead of vaccination with two strains (Wuhan virus + omicron BA.4/BA.5) or a “bivalent vaccine” which has been introduced To be used during this year (2023)

Advertisement – Continue reading the article below.

Recommend the use of vaccinesMonovalent XBB.1.5Dealing with Covid in 2024

And in order for vaccine production to reach the (American) public in July 2023, three companies producing mRNA vaccines and COVID-19 protein subunit vaccines have chosen Omicron XBB.1.5 as a model for producing vaccines for Used during the 2023-2024 season.

Advertisement – Continue reading the article below.

Recently, a research team from a medical university in the United States led by Prof. David D. Ho: a pioneering international researcher in the field of AIDS and HIV. that helped transform the HIV crisis from a deadly disease to become a chronic disease that can be controlled Through pioneering research in the field of antiretroviral therapy, Presented the work before publication in a medical journal. ” demonstrates the significant increase in efficacy of the XBB.1.5 monovalent vaccine, supporting the WHO recommendation to switch to the “XBB monovalent vaccine”, namely

Important efficacy of XBB.1.5 monovalent vaccine

• Antibodies stimulated by the XBB.1.5 monovalent vaccine can bind to and destroy the COVID-19 virus. There are a significant variety of species. Not only are omicrons XBB.1.5 and EG.5.1 the main strains currently circulating. But it can also resist new strains of Omicron that have just emerged at the end of this year, such as the descendants of Omicron XBB* which are HV.1, HK.3, JD.1.1 and the descendants of Omicron BA.2.86 which are JN.1

This points to the effectiveness of the monovalent XBB.1.5 vaccine, which stimulates the body to produce antibodies covering a broader spectrum of omicron strains than previous vaccines.

• Reduces the “immune system’s memory of the original species” or, in short, Immune imprinting: This research indicates that the monovalent /BA.5) or “bivalent vaccine”

Solving the problem of the body remembering the original strain of virus It prevents the creation of antibodies against the new virus.

Exposure to the COVID-19 virus or booster injections with vaccines that use the same virus repeatedly It may cause more harm than good. That is, a phenomenon called The immune system’s memory of the original strain (Immune imprinting), such as in the case of the COVID-19 vaccine. that has always used the original Wuhan virus But when our body encounters a new mutant virus that has changed slightly (minor change) from the original strain, such as Omicron XBB, our immune system still remembers the original form of the old virus that it learned from. Receive the “No Move On” vaccine, which prevents the production of antibodies against the new virus. or build little

A research team from Peking University led by Dr. Yunlong Richard Cao published important research in the medical journal “Nature” on November 22, 2023, proposing ways to alleviate the effects of memory loss. Remember our immune system to infection with the COVID-19 virus original breed and from the first dose of vaccination produced from the original strain of the Covid virus “Wuhan”

By being infected with Omicron 2 times or vaccinated with at least 2 injections of the Omicron XBB* strain, which will cause the body to produce a variety of antibodies. Able to bind to various positions on the virus’s spikes that are used to adhere to cells better.

Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting: https://www.nature.com/articles/s41586-023-06753-7

• Significantly effective in boosting immunity in individuals who have previously been infected with COVID-19.

However, important things to note about this research are:

• It is a research result of the antibody response to COVID-19. strains mainly in vitro and does not cover other aspects. of immune responses, such as T cell responses or mucosal immunity Long-term efficacy and real-world effectiveness were not part of this study.
• Not yet peer reviewed: The research results are awaiting peer review. This is an important process for validating scientific research results.

Read more news